Zhen Su, MD, MBA

CEO

Morengo Therapeutics

Sessions:

Speaker Engineering the Immune Synapse: Redefining How We Activate Anti-Tumor Immunity

Speaker Preclinical Rationale and Clinical Translation for Marengo's Selective Dual T Cell Agonist, Invikafusp Alfa as a Novel IO Backbone in Combination with ADCs